Clinical Trials Directory

Trials / Unknown

UnknownNCT05612893

Discover the Immune Signature of Sepsis Caused by Acute Pulmonary Infection: A Cohort Study

Status
Unknown
Phase
Study type
Observational
Enrollment
1,000 (estimated)
Sponsor
Capital Medical University · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Accepted

Summary

The goal of this observational study is to describe the immune signature of acute pulmonary infection.The main questions it aims to answer are: 1. Nasal mucosal immune response in patients with influenza infection 2. Difference of immune response between Viral sepsis and Bacterial sepsis 3. Immunological differences between Viral sepsis and Viral pneumonia

Detailed description

1. Aging could influence host immune response. Elderly people are more likely to progress to severe pneumonia than young people. Nasal mucosa is the initial infection site of influenza infection. Single cell sequencing of nasal mucosal cell that may provide valuable insights into host response to influenza infection. 2. Sepsis is a life-threatening organ dysfunction caused by a dysregulated host response to infection. Although bacteria are considered as the main pathgens of sepsis,SARS-CoV-2 or influenza infection also can cause multiple organ dysfunction which meet the definition of Sepsis 3.0. Viral sepsis has not received enough attention for a long time. It is important to understand the difference between viral sepsis and bacterial sepsis that may help to develop better strategies to diagnose and treat sepsis. 3. Viral pneumonia is one of the leading infectious cause of death woldwide.Pneumina is the most common cause of sepsis.The mechanism of viral pneumonia progressing to sepsis needs to be further investigated.

Conditions

Interventions

TypeNameDescription
OTHERpathogenThe patients were divided into groups according to the pathogen(bacteria or virus). The influenza upper respiratory tract infection cohort will be grouped mainly according to age.

Timeline

Start date
2022-11-16
Primary completion
2025-04-10
Completion
2025-09-10
First posted
2022-11-10
Last updated
2022-11-10

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT05612893. Inclusion in this directory is not an endorsement.